Evidence map›Paper›PMID 37372399›Full record

ArticleGenes2023

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma

Yong Gon Cho, Joonhong Park, Ji Yoon Han, Tae Yun Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yong Gon ChoDepartment of Laboratory Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.
Joonhong ParkDepartment of Laboratory Medicine, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.ORCID 0000-0001-7354-4234
Ji Yoon HanDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-4174-5266
Tae Yun KimDepartment of Thoracic and Cardiovascular Surgery, Jeonbuk National University Medical School and Hospital, Jeonju 54907, Republic of Korea.
Jeonbuk National University · KRCatholic University of Korea · KRJeonbuk National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical utility of circulating tumor DNA (ctDNA) in the early detection of tumor mutations for targeted therapy and the monitoring of tumor recurrence has been reported. However, the analytical validation of ctDNA assays is required for clinical application.

methodsThis study evaluated the analytical performance of the Oncomine Lung cfDNA Assay compared with the cobas

resultsUsing 20 ng of input cell-free DNA (cfDNA), the analytical sensitivities for

conclusionsThe Oncomine Lung cfDNA Assay can be used to identify plasma

Indexed as

Cell-Free Nucleic AcidsLung NeoplasmsErbB ReceptorsHumansLungMutationNeoplasm Recurrence, LocalCell-Free Nucleic AcidsEGFR protein, humanErbB Receptorsanalytical performancecobas® EGFR Mutation Test v2next-generation sequencingOncomine Lung cfDNA Assayplasma EGFR mutations

Identifiers

PMID37372399
PMCPMC10298348
OpenAlexW4379141914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.